Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 FAERS data

CONCLUSION: Thrombotic AEs in the FAERS data were about three times more frequently reported for emicizumab than for FVIII products. More research and efforts in the future are warranted for monitoring, elucidating, and preventing the potential risk of thrombotic AEs of hemophilia therapy, including emicizumab.PMID:38395359 | DOI:10.1016/j.jtha.2024.02.009
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research